Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

April 24, 2028

Study Completion Date

April 24, 2028

Conditions
Major Depressive Disorder
Interventions
DRUG

Placebo

saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.

DEVICE

intermittent theta burst stimulation

"10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds"

DRUG

intravenous citalopram hydrochloride (CIT)

CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.

DEVICE

continuous theta burst stimulation

"10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered"

Trial Locations (1)

90024

UCLA Depression Research and Clinic Program, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER